Nuvectis Pharma secured exclusive rights to experimental therapies NXP100 and NXP200 outside China, elevating it to late-stage clinical development. Roth Capital lifted the price target to $33 and Zacks elevated its rating to #2 Buy, reflecting bullish earnings estimates and growth prospects.
Nuvectis Pharma entered a licensing deal granting exclusive rights to two experimental drugs—NXP100 for complement-mediated diseases and NXP200 for BRAF-mutated cancers—outside of China, accelerating its shift to late-stage clinical development.
Roth Capital increased its price target to $33 from $20 while maintaining a Buy rating, and Zacks assigned a Rank #2 Buy, driven by upward revisions in earnings estimates and anticipated clinical milestones.
The company’s market capitalization is approximately $519.3 million, and its share price has fluctuated between $5.55 and $29.28 over the past year, reflecting heightened investor interest.
